Right. On Time.

At CMC Biologics, doing contract biopharmaceutical development and manufacturing right means offering more than a broad array of high quality services. It means providing solutions that meet client’s manufacturing needs today while positioning them for success tomorrow. Our clients’ commitment to patients inspires each member of the CMC Biologics’ team to do whatever is necessary – not just what is expected – to ensure the success of every project. Our customers know that patients can’t wait. Which is why we get it Right. Every Time.

Photo Tour of Facilities


News & Events


October 22, 2015

CMC Biologics Announces Agreement with Immunocore for Process Transfer, Scale-up and ommercial-Scale Manufacturing of IMCgp100


October 20, 2015

CMC Biologics Announces Appointment of New CEO

October 7, 2015

Governor Inslee’s Director of Life Science and Global Health Development, Maura Little, Presides Over CMC Biologics’ Ribbon Cutting Ceremony Commemorating the Bioreactor 6Pack™ Manufacturing Facility

August 12, 2015

CMC Biologics Enters into Agreement with the PATH Malaria Vaccine Initiative for Accelerated Development and Manufacturing of Monoclonal Antibodies


July 29, 2015

CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave’s Orbitopathy


June 30, 2015

CMC Biologics Expands GMP Manufacturing Capacity in the United States


May 20, 2015

CMC Biologics Expands European GMP Manufacturing Capacity


May 7, 2015

CMC Biologics Expands GMP Manufacturing Capacity in the United States and Europe


May 5, 2015

CMC Biologics in Commercial Supply Agreement with Emergent BioSolutions for FDA-Approved IXINITY®


March 19, 2015

CMC Biologics Recognized for Quality and Reliability at the 2015 CMO Leadership Awards Ceremony


January 30, 2015

Serendex Pharmaceuticals and CMC Biologics Enter Exclusive Agreement on Factor VIIa


December 16, 2014

CMC Biologics and OncoSynergy Enter into an Agreement for Accelerated Process Development and GMP Manufacture of an Investigational Drug to Combat Ebola


December 5, 2014

Joseph Wypych, 20-year Biopharmaceutical Executive, Joins CMC Biologics as General Manager, Seattle Facility


September 3, 2014

CMC Biologics and Zymeworks Enter into Agreement for Process Development and Clinical Manufacture of Bi-Specific Antibody Product Candidate


July 2, 2014

CMC Biologics Enters into Commercial Supply Agreement with Portola Pharmaceuticals for Manufacturing of First-In-Class Factor Xa Inhibitor Antidote Andexanet Alfa


June 17, 2014

CMC Biologics and MacroGenics Enter into Process Validation and Clinical Manufacturing Agreement for Commercialization of Next-Generation Oncology Product Candidate


May 6, 2014

CMC Biologics and MacroGenics Enter into a Process Development and Manufacturing Agreement for Oncology Product Candidate